MINNEAPOLIS, Dec. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted results of a study that compared the cost effectiveness of neuromodulation therapies for Overactive Bladder (OAB) patients over two years of treatment. The study compared percutaneous tibial nerve stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System versus sacral nerve stimulation (SNS). The article, "Costs of Neuromodulation Therapies for Overactive Bladder: Percutaneous Tibial Nerve Stimulation Versus Sacral Nerve Stimulation," will be published in the January 2013 edition of The Journal of Urology. An abstract is now available online at http://dx.doi.org/10.1016/j.juro.2012.08.085.
The study used average Medicare national reimbursement amounts for the cost evaluation of these two neuromodulation therapies with clinically comparable outcomes. The initial cost of PTNS therapy was $1,773 for 12 weekly treatments compared to $1,857 for the SNS test stimulation. Over two years, the cumulative discounted costs for PTNS therapy were estimated to be $3,850 compared to the SNS implant at $14,160. Under a wide variety of conditions, PTNS remained significantly less costly than SNS over two years of therapy for those patients with OAB refractory to conservative and drug therapy.
Melissa Martinson, PhD, lead author of the study stated, "This study demonstrates significant cost savings to the healthcare system when PTNS is used instead of SNS. In our current U.S. healthcare climate, maintaining the quality of care while also controlling costs is a central objective. We believe that studies like this can contribute to attaining that goal."
"This study demonstrates that PTNS remains a better value than SNS for OAB therapy for those patients who progress to neuromodulation therapy to treat their OAB symptoms," said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. "By demonstrating the cost over two years of SNS treatment for 100 patients was $1.4 million compared to approximately $385,000 for PTNS, we believe this study will interest payers who are now more attuned to comparative effectiveness research to determine the most cost-effective OAB care algorithm."
About the Urgent® PC Neuromodulation System
The Urgent PC Neuromodulation System is proprietary, minimally invasive, percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of overactive bladder (OAB) and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, Treasurer
Doug Sherk/Jenifer Kirtland
Chris Gale (Media), 646.201.5431
SOURCE Uroplasty, Inc.